Spectral Medical Inc
OTC Pink - Current Information:EDTXFView on Canadian Exchange

  • LAST PRICE
    0.4009
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    0.2784/ 25
  • Ask / Lots
    0.4841/ 25
  • Open / Previous Close
    --- / 0.4009
  • Day Range
    ---
  • 52 Week Range
    0.2700
    0.5499
  • Volume
    ---

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 8, 2024

      Show headlines and story abstract

    • 4:07PM ET on Friday Nov 08, 2024 by MT Newswires
      Companies Mentioned: EDT
      04:07 PM EST, 11/08/2024 (MT Newswires) -- ...

    • 10:27AM ET on Friday Nov 08, 2024 by MT Newswires
      Companies Mentioned: EDT
      10:27 AM EST, 11/08/2024 (MT Newswires) -- Spectral Medical (EDT.TO) on Friday reported a wider net loss on higher operating expenses. Net loss more than doubled to $10 million or $0.04 per share, from $3.8 million or $0.01 per share. The higher los...

    • 8:10AM ET on Friday Nov 08, 2024 by MT Newswires
      Companies Mentioned: EDT
      08:10 AM EST, 11/08/2024 (MT Newswires) -- ...

    • 8:07AM ET on Friday Nov 08, 2024 by Dow Jones
      Companies Mentioned: EDT

    • 8:00AM ET on Friday Nov 08, 2024 by Dow Jones
      Companies Mentioned: EDT
      Insurance 105 102 315 290 Depreciation and amortization 64 57 191 172 Interest expense 8 970 342 2,178 839 Foreign exchange loss (399) 46 129 (205) Share-based compensation 241 340 1,497 1,300 Other expense 163 320 704 289 Net loss on joint arrangement 6 - 41 - 205 Fair value adjustment derivative liabilities 8 6,156 81 6,088 (442) ---------------- ----- ----------- --------------- ----------- --------------- 10,497 4,072 20,194 10,292 ---------------- ----- ----------- --------------- ----------- --------------- Loss and comprehensive loss for the period from continuing operations (9,995) (3,675) (18,553) (9,059) ---------------- ----- ----------- --------------- ----------- --------------- Gain (loss) from discontinued operations 5 - (130) (3) (125) Loss and comprehensive loss for the period (9,995) (3,805) (18,556) (9,184) ---------------- ----- ----------- --------------- ----------- --------------- Basic and diluted loss from continuing operations per common share 11 (0.04) (0.01) (0.07) (0.03) Basic and diluted loss from discontinued operations per common share 11 (0.00) (0.00) (0.00) (0.00) Basic and diluted loss per common share 11 (0.04) (0.01) (0.07) (0.03) ---------------- ----------- --------------- ----------- --------------- Weighted average number of common shares outstanding - basic and diluted 11 281,705,359 278,604,718 280,269,516 278,569,902 ---------------- ----- ----------- --------------- ----------- --------------- Spectral Medical Inc. Condensed Interim Consolidated Statements of Changes in Shareholders' Deficiency In CAD (000s) (Unaudited) ---------------------------------------------------------------------------------------------------------------- Total Shareholders' Number of Share Contributed Share-based (deficiency) Notes Shares Capital surplus compensation Warrants Deficit equity $ $ $ $ $ $ Balance January 1, 2023 278,547,804 87,050 8,773 8,908 2,490 (109,775) (2,554) RSU released 10 28,457 11 - (11) - - - Warrants issued 10 - - - - 179 - 179 Warrants expired 10 - - 143 - (143) - - Loss and comprehensive loss for the period - - - - - (9,184) (9,184) Share-based compensation 10 - - - 1,300 - - 1,300 ------------------ ----- ----------- ------- ----------- ------------ -------- --------- ------------- Revised (Refer note 16) Balance, September 30, 2023 278,576,261 87,061 8,916 10,197 2,526 (118,959) (10,259) ------------------ ----- ----------- ------- ----------- ------------ -------- --------- ------------- Loss and comprehensive loss for the period - - - - - (6,478) (6,478) Share-based compensation 10 - - - 188 - - 188 ------------------ ----- ----------- ------- ----------- ------------ -------- --------- ------------- Balance December 31, 2023 278,576,261 87,061 8,916 10,385 2,526 (125,437) (16,549) ------------------ ----- ----------- ------- ----------- ------------ -------- --------- ------------- Balance January 1, 2024 278,576,261 87,061 8,916 10,385 2,526 (125,437) (16,549) Warrants exercised 10 982,500 618 - - (121) - 497 Warrants issued 10 - - - - 211 - 211 Warrants expired 10 - - 1,232 - (1,232) - - Share Options Exercised 10 1,867,627 1,163 - (524) - - 639 RSU released 10 114,210 50 - (50) - - - Notes Conversion 10 1,274,625 979 - - - - 979 Loss and comprehensive loss for the period - - - - - (18,556) (18,556) Share-based compensation 10 - - - 1,497 - - 1,497 ------------------ ----- ----------- ------- ----------- ------------ -------- --------- ------------- Balance September 30, 2024 282,815,223 89,871 10,148 11,308 1,384 (143,993) (31,282) ------------------ ----- ----------- ------- ----------- ------------ -------- --------- ------------- Spectral Medical Inc. Condensed Interim Consolidated Statements of Cash Flows In CAD (000s) (Unaudited) ------------------------------------------------------------------------------ Revised (Refer note 16) Nine months Nine months ended ended September 30, September 30, 2024 2023 Cash flow provided by (used in) Operating activities Loss and comprehensive loss for the period (18,556) (9,184) Adjustments for: Depreciation on right-of-use asset 92 73 Depreciation on property and equipment 85 87 Amortization of intangible asset 13 19 Amortization of deferred financing fee 788 373 Unrealized foreign exchange gain/loss 76 (155) Interest expense on lease liability 25 30 Accreted interest on notes payable 2,154 809 Share-based compensation expense 1,497 1,300 Net loss on joint venture arrangement - 205 Fair value adjustment derivative liabilities 6,088 (442) Changes in items of working capital: Trade and other receivables (151) 337 Inventories 48 36 Prepayments and other assets (261) (636) Trade and other payables (24) (781) Contract liabilities 1,603 (647) ------------------------------------------- -------------- --------------- Net cash used in operating activities (6,523) (8,576) Investing activities Purchase of property and equipment (28) (15) ------------------------------------------- -------------- --------------- Net cash used in investing activities (28) (15) Financing activities Financing charges paid (766) (641) Interest expense paid (794) (472) Lease liability payments (115) 110 Proceeds from share options exercised 639 - Proceeds from share warrants exercised 497 - Proceeds from 9% convertible notes issued 9,897 6,212 ------------------------------------------- -------------- --------------- Net cash provided by financing activities 9,358 5,209 Change in cash 2,807 (3,383) Cash, beginning of period 2,952 8,414 ------------------------------------------- -------------- --------------- Cash, end of period 5,759 5,031 ------------------------------------------- -------------- ------

Peers Headlines